Global Post-menopausal Osteoporosis Market: Industry Analysis and Forecast (2020-2026) by Drug Class, Distribution Channel, and Region

Global Post-menopausal Osteoporosis Market size was valued at US$ XX Mn in 2019 and the total revenue is expected to grow at XX% through 2020 to 2026, reaching nearly US$ XX Mn. The global Post-menopausal Osteoporosis market report is a comprehensive analysis of the industry, market, and key players. The report has covered the market by demand and supply-side by segments. The global Post-menopausal Osteoporosis market report also provides trends by market segments, technology, and investment with a competitive landscape. Global Post-menopausal Osteoporosis Market To know about the Research Methodology :- Request Free Sample Report

Global Post-menopausal Osteoporosis Market Overview

Osteoporosis is a skeletal disorder that has seen considerable market growth in recent years. It is characterized by the skeleton becoming fragile and loss of bone mass which results in fractures of a bone in the body. Post-menopausal Osteoporosis is a disease that ranges from loss of bone and hip fractures. Osteoporosis has become a worldwide health issue due to its high association with morbidity, mortality, as well as costs. The risk of overall osteoporosis increase as the person gets older because with age the density of bone decreases. Osteoporosis disease is a silent disease, symptoms will not appear until a fracture happens in the body. The effect of the disease can be seen in western countries as well now in Latin America and Asia-Pacific. According to a study, around 75 Million people suffer from osteoporosis disease in Japan, the USA, and Europe. And 3 million fractures are recorded by Europe annually People with low calcium in bone are more prone to this disease by ranging approximately 20% of the patients. Combined cases of hip, forearm, and spine fracture are estimated between 40 to 50% worldwide.

Global Post-menopausal Osteoporosis Market Dynamics

Some of the major factors like an aging population, decrease in the level of estrogen in the body, and changing living standards such as an increase in the consumption of alcohol, drugs, & smoking, increase in the incidences of loss of bone mass among people fueling the market growth globally. These rising incidences have proven beneficial for the healthcare industry and allowed various firms to expand and develop at a global level. As per the International Osteoporosis Foundation, it was observed that 25% of women and 5% of men who were aged 65 or above diagnosed with Osteoporosis disease. An increase in the commencing of joint ventures between major key players with several other factors such as the family history of members diagnosed with osteoporosis disease, long term usage of medicines that affects bone density or level of hormone in the body played an important role in the growth of the market. Sharing of infrastructure and knowledge of the medical field between companies opened the gates of optimism, opportunities, and a sense of product innovation as well as development, international tie-ups allowing companies to operate worldwide and invest in research and development more. However, intense competition between key players and strict regulations for the launch of new medical drugs combined with the cost associated with them will restraint the market from growing during the forecast period. The market was majorly hit by the COVID-19 pandemic in the last 2 years.

Global Post-menopausal Osteoporosis Market Segment Analysis

Global Post-menopausal Osteoporosis MarketBased on treatment, the market is segmented into Bisphosphonates, Hormones, Strontium Ranelate, Vitamin D, and Others. Of which the segment of Bisphosphonates is dominating. it is a group of drugs that reduces bone loss slowly and can be administered orally as well on instructions by the physician. Though pregnant women are not advised to take this drug as it causes muscle pain, dizziness, and nausea. It has several advantages such as a reduction in the percentage of hip and forearm fractures during osteoporosis disease, a rise in the improvement of the bone mass, density, and structure in the body, and reducing the risk of fractures among patients. Due to which the segment of Bisphosphonates is estimated to lead the market in the foreseeable future as well. The segment of Hormone Replacement Therapy has noted growth signs in the market due to the increasing use of this therapy among patients with deficiency of growth hormones in their body in major countries. Increase in the therapeutic area which is safe and less risky. On the other hand, the parathyroid hormone helps in the formation of new bones, and stimulating the bone cells which are in use at a large level reduces the risk of bone fractures. Besides this launch of new RANKL and SERMs novel drugs such as prolia, even which are used in increasing mineral in bones is anticipated to drive the market in the forecast period. By Distribution channel, the segment of the hospital pharmacy is expected to dominate in the forecast period due to an increase in the patients visiting the hospital with osteoporosis disease. Hospital pharmacy provides on-time medication and saves time. Increasing government support fueling the market growth. Whereas the segment of retail pharmacy is also growing due to the collaboration of doctors with the pharmacist in making available required drug for the patient suffering from Post-menopausal Osteoporosis.

Global Post-Menopausal Osteoporosis Market Regional Insights:

North America is the most dominant region in the market due to the high level of old age population in the region who are considering early treatments. The old-age population in the US is approximately 15%. As per the reports Department of Society of Human and Service of America, the number is estimated to reach 96 million by 2050 which is two times more than the 2014 records. Improper lifestyle and consumption of less protein and nutrient food have also increased the cases which in turn fueling the market growth in the segment. The European market is the second-largest market due to the continuous rise in innovations and research and development activities in the region. Developed economies of the region like France, Germany, England, and Italy are the major contributors in the region because of the presence of leading market players. France is regarded best country in terms of the medical and hospitality industry and is anticipated to dominate in the region. Asia Pacific is estimated to register the highest CAGR during the forecast period and is expected to grow highest, mainly due to investment in the healthcare industry and government interest in the rising number of diseases in the region. Developing nations like India, China, Japan, and South Korea are focused on launching new medication procedures and clinical trials along with medical tourism which allows medical professionals and students all over the world to learn and explore more. The Middle East and African region have also shown significant growth in the market due to an increase in the awareness among people about disease and shifting of pharmaceutical and biotech companies in the area due to the region's untapped market. However, the ME&A region is expected to grow at a slower rate as compared to other regions due to high labor cost and less availability of raw materials. UAE, Qatar, Saudi Arabia are the nations who are contributing most in the region. Government tie up and bilateral agreements are expected to increase the market in the region The objective of the report is to present a comprehensive analysis of the Global Post-menopausal Osteoporosis market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analysed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding the Global Post-menopausal Osteoporosis Market dynamics, structure by analyzing the market segments and project the Global Post-menopausal Osteoporosis Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Post-menopausal Osteoporosis Market make the report investor’s guide

Global Post-menopausal Osteoporosis Market Scope: Inquire before buying

Global Post-menopausal Osteoporosis Market

Global Post-menopausal Osteoporosis Market, by Region

• North America • Europe • Asia Pacific • Middle East and Africa • South America

Global Post-menopausal Osteoporosis Market Key Players

• Eli Lilly and CO. • Pfizer Inc., • Proctor & Gamble Co. • Amgen Inc. • Novartis International AG • Sanofi • AbbVie inc. • Merck & co Inc • GlaxoSmithKline Inc, • Tarsa Therapeutics • Teva Pharmaceuticals Industries • Novo Nordisk A/S • Oncobiologics • Paras Biopharmaceuticals Finland Oy
1. Preface 1.1. Market Definition and Key Research Objectives 1.2. Research Highlights 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Post-Menopausal Osteoporosis Market Size, by Market Value (US$ Mn) 3.1. Global Market Segmentation 3.2. Global Market Segmentation Share Analysis, 2019 3.2.1. Global 3.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 3.3. Geographical Snapshot of the Post-Menopausal Osteoporosis Products Market 3.4. Geographical Snapshot of the Post-Menopausal Osteoporosis Products Market, By Manufacturer share 4. Global Post-Menopausal Osteoporosis Market Overview, 2019-2026 4.1. Market Dynamics 4.1.1. Drivers 4.1.1.1. Global 4.1.1.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.2. Restraints 4.1.2.1. Global 4.1.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.3. Opportunities 4.1.3.1. Global 4.1.3.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.4. Challenges 4.1.4.1. Global 4.1.4.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.5. Industry Trends and Emerging Technologies 4.1.6. Porters Five Forces Analysis 4.1.6.1. Threat of New Entrants 4.1.6.2. Bargaining Power of Buyers/Consumers 4.1.6.3. Bargaining Power of Suppliers 4.1.6.4. Threat of Substitute Products 4.1.6.5. Intensity of Competitive Rivalry 4.1.7. Value Chain Analysis 4.1.8. Technological Roadmap 4.1.9. Regulatory landscape 4.1.10. Impact of the Covid-19 Pandemic on the Global Post-Menopausal Osteoporosis Market 5. Supply Side and Demand Side Indicators 6. Global Post-Menopausal Osteoporosis Mark Analysis and Forecast, 2019-2026 6.1 Post-Menopausal Osteoporosis Market Size & Y-o-Y Growth Analysis 7. Global Post-Menopausal Osteoporosis Market Analysis and Forecasts, 2019-2026 7.1. Market Size (Value) Estimates & Forecast By Drug-Class, 2019-2026 7.1.1. Bisphosphonates 7.1.2. Hormone Replacement Therapy 7.1.3. Selective Estrogen Receptor Modulator 7.1.4. RANK Ligand (RANKL) Inhibitor 7.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 7.2.1. Hospital Pharmacies 7.2.2. Retail Pharmacies 7.2.3. E-commerce pharmacies 7.3. Market Size (Value) Estimates & Forecast by Region, 2019-2026 7.3.1. North America 7.3.2. South America 7.3.3. Europe 7.3.4. Asia Pacific 7.3.5. Middle East and Africa 8. North America Post-Menopausal Osteoporosis Market Analysis and Forecasts, 2019-2026 8.1. Market Size (Value) Estimates & Forecast By Drug-Class, 2019-2026 8.1.1. Bisphosphonates 8.1.2. Hormone Replacement Therapy 8.1.3. Selective Estrogen Receptor Modulator 8.1.4. RANK Ligand (RANKL) Inhibitor 8.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 8.2.1. Hospital Pharmacies 8.2.2. Retail Pharmacies 8.2.3. E-commerce pharmacies 9. North America Post-Menopausal Osteoporosis Market Analysis and Forecasts, By Country 9.1. Market Size (Value) Estimates & Forecast By Country, 2019-2026 9.1.1. US 9.1.2. Canada 9.1.3. Mexico 10. U.S.A Post-Menopausal Osteoporosis Market Analysis and Forecasts, 2019-2026 10.1. Market Size (Value) Estimates & Forecast By Drug-Class, 2019-2026 10.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 11. Canada Post-Menopausal Osteoporosis Market Analysis and Forecasts, 2019-2026 11.1. Market Size (Value) Estimates & Forecast By Drug-Class, 2019-2026 11.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 12. Mexico Post-Menopausal Osteoporosis Market Analysis and Forecasts, 2019-2026 12.1. Market Size (Value) Estimates & Forecast By Drug-Class, 2019-2026 12.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 13. Europe Post-Menopausal Osteoporosis Market Analysis and Forecasts, 2019-2026 13.1. Market Size (Value) Estimates & Forecast By Drug-Class, 2019-2026 13.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 14. Europe Post-Menopausal Osteoporosis Market Analysis and Forecasts, By Country 14.1. Market Size (Value) Estimates & Forecast By Country, 2019-2026 14.1.1. U.K 14.1.2. France 14.1.3. Germany 14.1.4. Italy 14.1.5. Spain 14.1.6. Sweden 14.1.7. CIS Countries 14.1.8. Rest of Europe 15. U.K. Post-Menopausal Osteoporosis Market Analysis and Forecasts, 2019-2026 15.1. Market Size (Value) Estimates & Forecast By Drug-Class, 2019-2026 15.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 16. France Post-Menopausal Osteoporosis Market Analysis and Forecasts, 2019-2026 16.1. Market Size (Value) Estimates & Forecast By Drug-Class, 2019-2026 16.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 17. Germany Post-Menopausal Osteoporosis Market Analysis and Forecasts, 2019-2026 17.1. Market Size (Value) Estimates & Forecast By Drug-Class, 2019-2026 17.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 18. Italy Post-Menopausal Osteoporosis Market Analysis and Forecasts, 2019-2026 18.1. Market Size (Value) Estimates & Forecast By Drug-Class, 2019-2026 18.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 19. Spain Post-Menopausal Osteoporosis Market Analysis and Forecasts, 2019-2026 19.1. Market Size (Value) Estimates & Forecast By Drug-Class, 2019-2026 19.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 20. Sweden Post-Menopausal Osteoporosis Market Analysis and Forecasts, 2019-2026 20.1. Market Size (Value) Estimates & Forecast By Drug-Class, 2019-2026 20.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 21. CIS Countries Post-Menopausal Osteoporosis Market Analysis and Forecasts, 2019-2026 21.1. Market Size (Value) Estimates & Forecast By Drug-Class, 2019-2026 21.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 22. Rest of Europe Post-Menopausal Osteoporosis Market Analysis and Forecasts, 2019-2026 22.1. Market Size (Value) Estimates & Forecast By Drug-Class, 2019-2026 22.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 23. Asia Pacific Post-Menopausal Osteoporosis Market Analysis and Forecasts, 2019-2026 23.1. Market Size (Value) Estimates & Forecast By Drug-Class, 2019-2026 23.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 24. Asia Pacific Post-Menopausal Osteoporosis Market Analysis and Forecasts, by Country 24.1. Market Size (Value) Estimates & Forecast By Country, 2019-2026 24.1.1. China 24.1.2. India 24.1.3. Japan 24.1.4. South Korea 24.1.5. Australia 24.1.6. ASEAN 24.1.7. Rest of Asia Pacific 25. China Post-Menopausal Osteoporosis Market Analysis and Forecasts, 2019-2026 25.1. Market Size (Value) Estimates & Forecast By Drug-Class, 2019-2026 25.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 26. India Post-Menopausal Osteoporosis Market Analysis and Forecasts, 2019-2026 26.1. Market Size (Value) Estimates & Forecast By Drug-Class, 2019-2026 26.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 27. Japan Post-Menopausal Osteoporosis Market Analysis and Forecasts, 2019-2026 27.1. Market Size (Value) Estimates & Forecast By Drug-Class, 2019-2026 27.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 28. South Korea Post-Menopausal Osteoporosis Market Analysis and Forecasts, 2019-2026 28.1. Market Size (Value) Estimates & Forecast By Drug-Class, 2019-2026 28.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 29. Australia Post-Menopausal Osteoporosis Market Analysis and Forecasts, 2019-2026 29.1. Market Size (Value) Estimates & Forecast By Drug-Class, 2019-2026 29.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 30. ASEAN Post-Menopausal Osteoporosis Market Analysis and Forecasts, 2019-2026 30.1. Market Size (Value) Estimates & Forecast By Drug-Class, 2019-2026 30.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 31. Rest of Asia Pacific Post-Menopausal Osteoporosis Market Analysis and Forecasts, 2019-2026 31.1. Market Size (Value) Estimates & Forecast By Drug-Class, 2019-2026 31.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 32. Middle East Africa Post-Menopausal Osteoporosis Market Analysis and Forecasts, 2019-2026 32.1. Market Size (Value) Estimates & Forecast By Drug-Class, 2019-2026 32.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 33. Middle East Africa Post-Menopausal Osteoporosis Market Analysis and Forecasts, by Country 33.1. Market Size (Value) Estimates & Forecast by Country, 2019-2026 33.1.1. South Africa 33.1.2. GCC Countries 33.1.3. Egypt 33.1.4. Nigeria 33.1.5. Rest of ME&A 34. South Africa Post-Menopausal Osteoporosis Market Analysis and Forecasts, 2019-2026 34.1. Market Size (Value) Estimates & Forecast By Drug-Class, 2019-2026 34.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 35. GCC Countries Post-Menopausal Osteoporosis Market Analysis and Forecasts, 2019-2026 35.1. Market Size (Value) Estimates & Forecast By Drug-Class, 2019-2026 35.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 36. Egypt Post-Menopausal Osteoporosis Market Analysis and Forecasts, 2019-2026 36.1. Market Size (Value) Estimates & Forecast By Drug-Class, 2019-2026 36.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 37. Nigeria Post-Menopausal Osteoporosis Market Analysis and Forecasts, 2019-2026 37.1. Market Size (Value) Estimates & Forecast By Drug-Class, 2019-2026 37.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 38. Rest of ME&A Post-Menopausal Osteoporosis Market Analysis and Forecasts, 2019-2026 38.1. Market Size (Value) Estimates & Forecast By Drug-Class, 2019-2026 38.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 39. South America Post-Menopausal Osteoporosis Market Analysis and Forecasts, 2019-2026 39.1. Market Size (Value) Estimates & Forecast By Drug-Class, 2019-2026 39.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 40. South America Post-Menopausal Osteoporosis Market Analysis and Forecasts, by Country 40.1. Market Size (Value) Estimates & Forecast by Country, 2019-2026 40.1.1. Brazil 40.1.2. Argentina 40.1.3. Rest of South America 41. Brazil Post-Menopausal Osteoporosis Market Analysis and Forecasts, 2019-2026 41.1. Market Size (Value) Estimates & Forecast By Drug-Class, 2019-2026 41.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 42. Argentina Post-Menopausal Osteoporosis Market Analysis and Forecasts, 2019-2026 42.1. Market Size (Value) Estimates & Forecast By Drug-Class, 2019-2026 42.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 43. Rest of South America Post-Menopausal Osteoporosis Market Analysis and Forecasts, 2019-2026 43.1. Market Size (Value) Estimates & Forecast By Drug-Class, 2019-2026 43.2. Market Size (Value) Estimates & Forecast By Distribution Channel, 2019-2026 44. Competitive Landscape 44.1. Geographic Footprint of Major Players in the Global Post-Menopausal Osteoporosis Market 44.2. Competition Matrix 44.2.1. Competitive Benchmarking of Key Players By Price, Presence, Market Share, Distribution Channels and R&D Investment 44.2.2. New Product Launches and Product Enhancements 44.2.3. Market Consolidation 44.2.3.1. M&A by Regions, Investment and Verticals 44.2.3.2. M&A, Forward Integration and Backward Integration 44.2.3.3. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements 44.3. Company Profile : Key Players 44.3.1. Paras Biopharmaceuticals Finland Oy 44.3.1.1. Company Overview 44.3.1.2. Financial Overview 44.3.1.3. Geographic Footprint 44.3.1.4. Product Portfolio 44.3.1.5. Business Strategy 44.3.1.6. Recent Developments 45.3.2 Eli Lilly and CO. 45.3.3 Pfizer Inc. 45.3.4 Proctor & Gamble Co. 45.3.5 Amgen Inc. 45.3.6 Novartis International AG 45.3.7 Sanofi 45.3.8 AbbVie inc. 45.3.9 Merck & co Inc 45.3.10 GlaxoSmithKline Inc, 45.3.11 Tarsa Therapeutics 45.3.12 Teva Pharmaceuticals Industries 45.3.13 Novo Nordisk A/S 45.3.14 Oncobiologics,

About This Report

Report ID 106773
Category Food & Beverages
Published Date Jun 2021
Updated Date
Contact Us